Capital Analysts LLC’s Eli Lilly LLY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $6.38M | Sell |
5,315
-20
| -0.4% | -$20.4K | 0.15% | 123 |
|
|
2026
Q1 | $4.91M | Buy |
5,335
+3,359
| +170% | +$3.41M | 0.13% | 137 |
|
|
2025
Q4 | $2.12M | Sell |
1,976
-11
| -0.6% | -$10.5K | 0.06% | 230 |
|
|
2025
Q3 | $1.52M | Sell |
1,987
-98
| -5% | -$72.9K | 0.04% | 254 |
|
|
2025
Q2 | $1.63M | Sell |
2,085
-57
| -3% | -$44.3K | 0.05% | 231 |
|
|
2025
Q1 | $1.77M | Sell |
2,142
-1,415
| -40% | -$1.18M | 0.07% | 206 |
|
|
2024
Q4 | $2.75M | Buy |
3,557
+871
| +32% | +$721K | 0.11% | 152 |
|
|
2024
Q3 | $2.38M | Buy |
2,686
+1,626
| +153% | +$1.46M | 0.1% | 167 |
|
|
2024
Q2 | $960K | Buy |
1,060
+16
| +2% | +$12.8K | 0.04% | 250 |
|
|
2024
Q1 | $812K | Sell |
1,044
-40
| -4% | -$28.5K | 0.04% | 265 |
|
|
2023
Q4 | $632K | Sell |
1,084
-39
| -3% | -$22.8K | 0.03% | 286 |
|
|
2023
Q3 | $603K | Buy |
1,123
+78
| +7% | +$40.2K | 0.03% | 275 |
|
|
2023
Q2 | $490K | Buy |
1,045
+703
| +206% | +$295K | 0.03% | 294 |
|
|
2023
Q1 | $117K | Buy |
342
+43
| +14% | +$14.5K | 0.01% | 449 |
|
|
2022
Q4 | $109K | Sell |
299
-11
| -4% | -$3.9K | 0.01% | 485 |
|
|
2022
Q3 | $100K | Buy |
310
+27
| +10% | +$8.55K | 0.01% | 448 |
|
|
2022
Q2 | $92K | Hold |
283
| – | – | 0.01% | 443 |
|
|
2022
Q1 | $81K | Hold |
283
| – | – | 0.01% | 469 |
|
|
2021
Q4 | $78K | Hold |
283
| – | – | ﹤0.01% | 495 |
|
|
2021
Q3 | $65K | Sell |
283
-8
| -3% | -$1.97K | ﹤0.01% | 544 |
|
|
2021
Q2 | $67K | Buy |
291
+1
| +0.3% | +$201 | ﹤0.01% | 522 |
|
|
2021
Q1 | $55K | Buy |
290
+56
| +24% | +$11K | ﹤0.01% | 574 |
|
|
2020
Q4 | $40K | Sell |
234
-2
| -0.8% | -$299 | ﹤0.01% | 441 |
|
|
2020
Q3 | $35K | Hold |
236
| – | – | ﹤0.01% | 451 |
|
|
2020
Q2 | $39K | Hold |
236
| – | – | ﹤0.01% | 400 |
|
|
2020
Q1 | $33K | Sell |
236
-161
| -41% | -$22.1K | ﹤0.01% | 388 |
|
|
2019
Q4 | $52K | Hold |
397
| – | – | 0.01% | 387 |
|
|
2019
Q3 | $44K | Hold |
397
| – | – | ﹤0.01% | 398 |
|
|
2019
Q2 | $44K | Hold |
397
| – | – | ﹤0.01% | 386 |
|
|
2019
Q1 | $51K | Buy |
397
+111
| +39% | +$13.5K | 0.01% | 344 |
|
|
2018
Q4 | $33K | Sell |
286
-21
| -7% | -$2.35K | ﹤0.01% | 366 |
|
|
2018
Q3 | $33K | Hold |
307
| – | – | ﹤0.01% | 361 |
|
|
2018
Q2 | $26K | Sell |
307
-256
| -45% | -$21K | ﹤0.01% | 387 |
|
|
2018
Q1 | $44K | Buy |
563
+218
| +63% | +$17.6K | 0.01% | 324 |
|
|
2017
Q4 | $29K | Sell |
345
-93
| -21% | -$7.91K | ﹤0.01% | 344 |
|
|
2017
Q3 | $38K | Buy |
438
+93
| +27% | +$7.63K | 0.01% | 326 |
|
|
2017
Q2 | $28.4K | Hold |
345
| – | – | ﹤0.01% | 338 |
|
|
2017
Q1 | $29.1K | Hold |
345
| – | – | ﹤0.01% | 295 |
|
|
2016
Q4 | $25K | Sell |
345
-8,037
| -96% | -$599K | ﹤0.01% | 307 |
|
|
2016
Q3 | $673K | Buy |
8,382
+347
| +4% | +$27.8K | 0.13% | 116 |
|
|
2016
Q2 | $633K | Buy |
8,035
+120
| +2% | +$9.03K | 0.13% | 127 |
|
|
2016
Q1 | $570K | Buy |
7,915
+466
| +6% | +$35.3K | 0.11% | 141 |
|
|
2015
Q4 | $628K | Buy |
+7,449
| New | +$618K | 0.13% | 125 |
|
Other funds holding LLY
Capital Analysts LLC's LLY Position: Q2 2026 in Review
Capital Analysts LLC reduced its Eli Lilly (LLY) stake by 0.37% in Q2 2026, selling an estimated $20.4K and leaving 5,315 shares worth $6.38M. The position accounts for 0.15% of the portfolio, ranked #123.
Capital Analysts LLC first reported a position in LLY in Q4 2015 and has held it in 43 quarters since. 4,602 funds tracked by Wall St. Rank hold LLY as of Q2 2026.
- Capital Analysts LLC held 5,315 shares of Eli Lilly worth $6.38M as of Q2 2026.
- Capital Analysts LLC sold 20 Eli Lilly shares in Q2 2026, an estimated $20.4K.
- Eli Lilly made up 0.15% of Capital Analysts LLC's portfolio in Q2 2026, its #123 holding.
- Capital Analysts LLC first reported a position in Eli Lilly in Q4 2015 and has held it in 43 quarters since.
- 4,602 funds tracked by Wall St. Rank held Eli Lilly as of Q2 2026.
Based on Capital Analysts LLC's 13F filing for Q2 2026, filed 5 Aug 2026.